Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Baxter To Buy Prism, Getting Heart Drug
by Rick Mullin
April 25, 2011
| A version of this story appeared in
Volume 89, Issue 17
Baxter International has agreed to acquire Prism Pharmaceuticals, a privately held drug firm that recently received FDA approval for the antiarrhythmic agent Nexterone. Baxter will pay $170 million at closing and up to $168 million in sales-based milestones. Sold as a ready-to-use premixed intravenous bag, Nexterone requires no admixing, Baxter says, thus eliminating the risk of medication errors as a result of compounding. Prism had previously selected Baxter as its contract manufacturer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter